DePuy Synthes, the orthopedics business of Johnson & Johnson, has reached an agreement to add a dual-mobility acetabular cup to its portfolio of hip replacement implants, instruments and biologics. This move comes as a result of an agreement between DePuy Ireland Unlimited Company (based in Ringaskiddy) and Société d’Etude, de Recherche et de Fabrication (SERF), based in Décines-Charpieu, France..
DePuy Synthes Adds French Dual Mobility System to Hip Portfolio
1 min read Premium comments
Secondary#depuysynthes#acetabularcup#hip
SERF was created in 1973 to facilitate the design and manufacture of orthopedic implants. According to Aaron Villaruz, global platform leader for DePuy Synthes hips, SERF was the company that developed the first dual mobility hip system with the late Professor Gilles Bousquet, M.D., professor at the University Hospital of Saint-Etienne (France), over 30 years ago.
According to DePuy, “SERF has long been an innovator in dual-mobility technology, having developed the dual-mobility concept in the 1970s. DePuy Synthes is a global leader in hips, and its deep and broad portfolio includes the CORAIL Hip Stem, which has a 96.3% survivorship at 25 years.”
“Per the agreement, DePuy Synthes plans to provide the latest SERF dual-mobility acetabular cup under its own brand name to global markets beginning in the latter half of 2018 subject to regulatory approvals in the U.S. and Europe (additional registrations in certain other geographies are planned to follow).”
“The long-term trust that orthopaedic surgeons have placed in both companies’ products is a testament to their demonstrated performance, and we look forward to integrating SERF’s dual-mobility technology with CORAIL and several of our other hip stems,” said Villaruz.
Furthermore, Villaruz told OTW, “SERF is the right choice because they are the pioneer in dual mobility and their implants have excellent clinical history. DePuy Synthes is responsibly entering the dual mobility market with a proven technology. The agreement is unique in that it allows us to enter the market as quickly as possible, relying on proven manufacturing processes and technology.”
“This technology has evolved over time through improved design, materials, fixation & clinical experience with more than 250,000 Dual Mobility cups. The clinical heritage and evolution of this dual mobility has been refined into the product we will offer this year.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.